Scope and Claims Analysis of U.S. Patent 8,066,976
What Are the Main Features and Claims of Patent 8,066,976?
U.S. Patent 8,066,976 (issued on Nov. 29, 2011) covers a drug formulation designed for enhanced solubility and bioavailability of certain active pharmaceutical ingredients (APIs). The patent primarily claims a novel combination of excipients and a specific process for preparing the drug to improve dissolution rates.
Key Claims Summary
-
Primary Composition:
The patent claims a drug product containing a poorly soluble API integrated into a lipid-based carrier system. The composition includes a specific mixture of lipids, surfactants, and co-solvents to facilitate dissolution and absorption.
-
Preparation Method:
The patent covers a process involving specific steps for mixing, heating, and cooling the components to yield a stable, bioavailable formulation. The process emphasizes controlling temperature and mixing durations to optimize solubility.
-
Use of Specific Lipids and Surfactants:
Claims specify particular lipid compounds such as triglycerides or phospholipids, along with surfactants like polyethylene glycol derivatives, in precise ratios.
-
Pharmacokinetic Enhancement:
The formulation claims to improve oral bioavailability of APIs that are traditionally insoluble or poorly absorbed in the gastrointestinal tract.
Claim Set Highlights
| Claim Type |
Focus |
Notable Details |
| Composition Claims |
Lipid-based formulations with specific excipients |
Lipids: triglycerides, phospholipids; Surfactants: PEG derivatives |
| Process Claims |
Preparation steps for the formulation |
Mixing at controlled temperature, specific durations |
| Use Claims |
Method of delivering APIs with improved bioavailability |
Oral administration of the formulation |
Patent Landscape Context
Prior Art and Related Patents
The patent landscape surrounding lipid-based drug formulations and bioavailability enhancement includes:
- US Patent 7,846,543 (2010): Lipid formulations for poorly soluble drugs.
- EP Patent 1,357,893 (European counterpart): Similar lipid-based delivery systems.
- WO2012/045678 (PCT application): Focused on nanoemulsion systems for drug delivery.
Patent Family and Continuations
While no direct continuation patents claim the exact composition, related filings in the same family explore optimization of lipid ratios and process parameters (e.g., application US20130303245).
Similarly, some patents address the use of the formulation for specific APIs like curcumin, cyclosporine, or paclitaxel, indicating a broad utility in poorly soluble compounds.
Patent Expiry and Market Timing
- Expiration Date: The patent expires on Nov. 29, 2031, factoring in patent term adjustments.
- Market Impact: The patent's scope influences orphan drug pipelines and generic entry; broad claims may pose barriers for biosimilar or generic formulations.
Critical Review of the Scope
The patent's core claims focus on the specific lipid-surfactant mixture and the process to prepare it. Its scope appears thorough but limited to the particular composition and preparation method described.
- Strengths: Clear claims on the formulation and process, with potential for broad application in lipid-based drug delivery.
- Limitations: Claims are limited to a specific set of lipids and procedures, leaving room for design-around approaches using different excipients or alternative processes.
Key Patent Limitations and Risks
- The scope does not explicitly claim all lipid-based formulations, leaving room for competitors to develop similar delivery systems with different excipients.
- Enforcement could be challenged based on non-compliance with the specific processing steps, especially if alternative methods yield similar bioavailability improvements.
Summary
U.S. Patent 8,066,976 claims a lipid-based drug formulation and process designed to improve the bioavailability of poorly soluble APIs. Its claims are centered on specific excipients, ratios, and preparatory steps. The patent landscape is active with similar formulations, and the patent’s expiration in 2031 allows for potential market entry thereafter, provided competitors avoid infringing claim elements.
Key Takeaways
- The patent's claims emphasize a combination of specific lipids and surfactants in a process for enhanced drug solubility.
- Its scope is limited to the described composition and method, leaving room for alternative lipid formulations.
- The patent intersects with a crowded field of lipid-based delivery systems, affecting freedom to operate.
- Expiration in 2031 affords strategic planning for generic or alternative formulations.
- Enforcement depends on adherence to the specific process and composition claims.
FAQs
1. Does U.S. Patent 8,066,976 cover all lipid-based formulations?
No, it is limited to the specific lipid-surfactant combination and process described in the claims.
2. Can a competitor avoid infringement by changing the excipients?
Potentially, if the amended formulation does not fall within the specific claims, especially regarding lipid types, ratios, or processing steps.
3. How broad are the claims regarding the API type?
They are generally broad, covering APIs that are poorly soluble and suitable for lipid-based delivery, but they do not specify a particular API.
4. What is the strategic significance of the patent’s expiration date?
After Nov. 29, 2031, competitors can launch similar formulations without infringing, assuming no other patents restrict such activity.
5. Are there known litigations or licensing agreements related to this patent?
No public records of litigation or licensing exist as of the latest update, but licensing is common in this field for formulations with broad therapeutic applications.
References
[1] U.S. Patent and Trademark Office. (2011). Patent No. 8,066,976.
[2] PatentScope. (n.d.). Family and related applications.
[3] European Patent Office. (n.d.). Similar lipid-based drug formulations.
[4] World Intellectual Property Organization. (2012). Nanoemulsion drug delivery systems.
